State of the Art EGFR targeting therapies in mCRC “Personalized Treatment for mCRC”

4 Educational meetings were held:

  • 22nd November 2011, Prague – 32 participants

  • 3rd  February   2012, Warsaw – 27 participants

  • 12th April 2013 Bratislava

  • 26th April 2o13 Prague

CECOG has now finished two studies (the CORE -1 and the CORE -2 Study) which have applied EGFR Inhibitors in metastatic Colorectal Cancer. CORE 1 compared FOLFOX and FOLFIRI both in combination with Cetuximab, CORE 2 investigated the ability to administer Cetuximab every two weeks.

Whereas the first trial was published in the World Journal of Gastroenterology, the second is still being evaluated regarding the results, but has provided some very interesting preliminary data. In order to further expand on these activities, CECOG is planning to hold educational meetings on the issue within our area.


At the end of the lectures, participants will be able to understand the principles, indications, techniques and limitations of anti-EGFR antibody treatment in metastatic colorectal cancer, will understand efficacy of EGFR antibody therapy in various lines of treatment. They will participate in case discussions and will learn to control therapy-associated side effects.

Prof. Zielinski on Education

CECOG Contact Information

Please feel free to contact us if you have any questions.